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BETA-ADRENERGIC blocking agents have been used with success in angina
pectoris (Alleyne et al, 1963; Hamer et al, 1964; Keelan, 1965); and in various
cardiac arrthymias (Besterman and Friedlander, 1965). Snow (1965) administered
10-20 mg. of propranolol (Inderal-I.C.I.) eight-hourly to 45 patients with myo-
cardial infarction and found that the mortality in the treated cases was 16 per cent.
compared with 35 per cent. in the controls. Snow's results have been challenged by
Balcon et al (1966) and by Clausen et al (1966).
Agents of this type can reduce the cardiac output and may therefore predispose
to heart failure. It was felt that this risk was acceptable if they would prolong the
survival time after acute myocardial infarction.
PLAN OF TRIAL
Earlier work had suggested that about 30 per cent. of patients treated in hospital
for acute myocardial infarction died within 4 weeks, most of these within the first
few days. It was decided that if the administration of propranolol reduced this
death rate to 15 per cent. it would be of clinical value. Consequently the trial was
designed to have a 95 per cent. probability of detecting, at the conventional 5 per
cent. probability level of significance, a critical difference of 15 per cent. in the
survival rate at 4 weeks after onset of a group of patients on propranolol and a
control group.
Patients were admitted to the trial if they had a clinical history of myocardial
infarction within the preceding 24 hours and electrocardiographic changes com-
patible with this diagnosis. Serum glutamic oxalacetic transaminase (S.G.O.T.)
levels were estimated but no patient was admitted to the trial on this criterion alone.
Patients who had been admitted on clinical grounds and in whom subsequent
cardiographs failed to reveal the expected changes were withdrawn from the trial.
No patient with a heart rate of under 60 beats per minute was admitted to the
trial, whether this was due to sinus bradycardia or atrio-ventricular block. Asthma
or broncho-spasm was also regarded as a contra-indication, as was a systolic blood
pressure less than 90 mm. Hg. They were all electrocardiographically monitored in
the first 48 hours at least. Propranolol was given in the dose of 40 mgms. six-
hourly for 28 days. This is a larger dose than those used by Snow (1965), Balcon
et al (1966) and Clausen et al (1966). Particular attention was directed to the
development of heart failure, rhythm changes and further episodes of cardiac pain.
This is a restricted sequential trial with the valuation of treatments by observed
preferences between patients within pairs, each member of a pair being differently
treated. The design was described by Armitage (1960). Treatments were allotted at
random to each pair; preferences are defined as pairs in which one patient was
successfully treated. The criterion of success was survival at 4 weeks.
127In Armitage's (1960) notation the specific sequential plan required to satisfy
the conditions is identified by the specification given in Fig. 1.
Each patient was allotted to one of four sub-groups according to age, under 60
years, 60 years and over, and sex. Within each of two hospitals and within each
of the sub-groups patients were allotted to two treatment groups at random in
accordance with a previously prepared plan.
RESULTS
In all, 107 patients were admitted to the trial during the period December, 1965
September, 1966. Of these, 8 were withdrawn from the trial as they did not meet
the above criteria, 2 were on propranolol and 6 on the placebo. This left 42 pairs
of patients and of these only 12 yielded preferences, of which 7 were for propranolol.
These preferences are plotted on Fig. 1. If this trend continued until the boundary
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indicating non-significance was crossed it was estimated that the patients would
have to be admitted to the trial for the next six years.
TABLE I
Mortality rates
Treatment
Result of treatment Propranolol Placebo
Died within 4 weeks of onset 10 (19.4) 12 (25.5)
Survived 4 weeks 42 35
Total 52 47
x2=0.261 D.F.=1, 0.7>P>0.5
Figures in brackets give percentage number of deaths in each treatment regime.
128TABLE IL
Mortality rates by treatment regime, age and sex
Males Females
Treatment under 60 60and over under 60 60andover
Propranolol 5.9 (17) 33.3 (21) -(4) 20.0 (10)
Placebo - ( 11) 26.1 (23) -(2) 54.5 (11)
Number of patients in each sub-group is given in brackets.
In view of the apparent similarity of the effects of the two treatments, it was
decided to terminate the sequential trial and compare the death rates between
treatment regimes by convential x2 tests or exact probability tests. The 99 patients
who completed the trial were included in this analysis. Table I shows that there
was no significant difference (at P<0.05) between the mortality of patients on
propranolol and those on the placebo. Table II shows the mortality rates in each
treatment regime within each of the four age-sex sub-groups. The number of
patients of either sex in the younger age group was too few to permit a comparison
of mortality to be made. In the older age group, no significant difference was
found in the mortality for either males (X2=0.036, D.F.= I, 0.9>P>0.8), or
females (P, double tail=0.183).
COMPLICATIONS
No serious side effects were encountered during this trial. Eighteen cases
developed heart failure in the control group, as against twenty on propranolol.
There was no evidence that this procedure precipitated heart failure in any case.
In two patients on propranolol the systolic blood pressure fell to 80. After the
omission of one dose the pressure rose within a few hours and remained satis-
factory.
TABLE III
Incidence per cent. of complications
COMPLICATION
Treatment No. of Heart Rhythm Further attacks
patients failure change of heart pai.n
Propranolol 52 38.5 13.5 26.9
Placebo 47 38.3 21.3 21.3
x2 0.0005 0.582 0.176
D.F. 1 1 I
P. 0.98-0.99 0.30-0.5G 0.50-0.70
Table III shows the percentage number of patients with heart failure, rhythm
change, and further attacks of heart pain for each treatment regime. The arrythmias
encountered included multiple ectopic beats, auricular tachycardia, auricular
fibrillation, ventricular tachycardia, and ventricular fibrillation. No significant
129difference was found in percentage incidence for any particular complication
(see X2's of Table 3). Similar trends were found when the incidences were compared
within each age and sex sub-group.
SUMMARY
In a trial of propranolol (40 mgms. six-hourly) in patients with acute myocardial
infarction, no significant difference in mortality at 4 weeks was demonstrated
between the drug and the placebo. The incidence of heart failure, cardiac arrythmias,
and further episodes of cardiac pain was similar in both groups.
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